Study of Iguratimod for chronic graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have had a stem cell transplant from a donor.
- You have chronic GVHD symptoms that need ongoing treatment.
- You have already tried between 1 and 5 different treatments for chronic GVHD.
- Your current steroid dose (like prednisone) has been stable for at least 2 weeks, or you've had trouble reducing it.
- You are able to take pills by mouth and do not have severe digestive problems.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (an IL6-receptor inhibitor plus belumosudil) for people with chronic graft-versus-host disease that hasn't improved with belumosudil alone. It aims to see if this combination is safe and helpful for controlling cGVHD symptoms.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial tests a combination of two medications (belumosudil and ruxolitinib) for people with chronic graft-versus-host disease (cGvHD) that has not improved with steroid treatment. The goal is to see if this combination can better control the condition.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.